4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Pheochromocytoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 78 ongoing clinical trials involving Pheochromocytoma
Of the 78 trials,51 trials are in Phase II
Furthermore, 17 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Pheochromocytoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Pheochromocytoma, an Oncology condition. The largest number of ongoing clinical trials for Pheochromocytoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Pheochromocytoma-related drug trials.

National Cancer Institute US: The leading ongoing Pheochromocytoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Pheochromocytoma-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, Ipsen SA, Mayo Clinic and University of Texas Southwestern Medical Center are among other notable clinical trial sponsors involved in Pheochromocytoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Pheochromocytoma

lobenguane I 131 (Azedra), Atenolol and Cyclophosphamide are among the key marketed drugs involving Pheochromocytoma.

Iobenguane I 131 (Azedra) is a therapeutic radio-pharmaceutical agent. It functions via NAD+ ADP Ribosyltransferase (Poly Adenosine Diphosphate Ribose Polymerase or PARP or EC 2.4.2.30) Inhibitor mechanism of action. Iobenguane is formulated as injectable solution for intravenous route of administration. Iobenguane was first approved in 2018 and is marketed solely in the US by Progenics Pharmaceuticals Inc.

Atenolol is an antihypertensive and anti-anginal agent. It functions via Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1) Antagonist mechanism of action. Atenolol is formulated as tablets for oral route of administration. Atenolol is marketed solely in China by Gansu Lanyao Pharmaceutical Co Ltd.